Which has stronger valuation & earnings, SVRA or FULC?

Savara is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Fulcrum Therapeutics N/A N/A -$74.88M -$1.21 N/A

Is SVRA or FULC more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Fulcrum Therapeutics N/A -25.38% -24.15%

Does the media refer more to SVRA or FULC?

In the previous week, Fulcrum Therapeutics had 5 more articles in the media than Savara. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 0.67 beat Fulcrum Therapeutics' score of 0.18 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KURA or FULC?

In the previous week, Kura Oncology had 12 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 19 mentions for Kura Oncology and 7 mentions for Fulcrum Therapeutics. Kura Oncology's average media sentiment score of 0.85 beat Fulcrum Therapeutics' score of 0.18 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, FULC or SANA?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fulcrum Therapeutics N/A N/A -$74.88M -$1.21 N/A Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A

Is FULC or SANA more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -25.38% -24.15% Sana Biotechnology N/A -103.02% -39.16%

Does the media prefer FULC or SANA?

In the previous week, Fulcrum Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 5 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.54 beat Fulcrum Therapeutics' score of 0.18 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FULC or LXRX?

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.28 beat Fulcrum Therapeutics' score of 0.18 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, FBRX or FULC?

Forte Biosciences is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Fulcrum Therapeutics N/A N/A -$74.88M -$1.21 N/A

Is FBRX or FULC more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Fulcrum Therapeutics N/A -25.38% -24.15%

Does the media favor FBRX or FULC?

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Forte Biosciences. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 3 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.38 beat Fulcrum Therapeutics' score of 0.18 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fulcrum Therapeutics (FULC) Competitors

$3.82 -0.01 (-0.13%)

As of 01:37 PM Eastern

Compare

FULC vs. SVRA, KURA, SANA, LXRX, and FBRX

Should you buy Fulcrum Therapeutics stock or one of its competitors? Fulcrum Therapeutics's main competitors and comparable companies include Savara (SVRA), Kura Oncology (KURA), Sana Biotechnology (SANA), Lexicon Pharmaceuticals (LXRX), and Forte Biosciences (FBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fulcrum Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Savara is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.21	N/A

Savara has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market.

87.9% of Savara shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Fulcrum Therapeutics had 5 more articles in the media than Savara. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 0.67 beat Fulcrum Therapeutics' score of 0.18 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics' return on equity of -25.38% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

Savara presently has a consensus price target of $10.14, suggesting a potential upside of 82.26%. Fulcrum Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 114.38%. Given Fulcrum Therapeutics' higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Fulcrum Therapeutics beats Savara on 9 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kura Oncology presently has a consensus target price of $25.40, indicating a potential upside of 102.92%. Fulcrum Therapeutics has a consensus target price of $8.20, indicating a potential upside of 114.38%. Given Fulcrum Therapeutics' higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Kura Oncology has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market.

In the previous week, Kura Oncology had 12 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 19 mentions for Kura Oncology and 7 mentions for Fulcrum Therapeutics. Kura Oncology's average media sentiment score of 0.85 beat Fulcrum Therapeutics' score of 0.18 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	14.42	-$278.67M	-$3.37	N/A
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.21	N/A

Fulcrum Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Fulcrum Therapeutics' return on equity of -25.38% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

Summary

Fulcrum Therapeutics beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Sana Biotechnology?

Fulcrum Therapeutics (NASDAQ:FULC) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Fulcrum Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 114.38%. Sana Biotechnology has a consensus price target of $9.33, suggesting a potential upside of 144.01%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Fulcrum Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 5 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.54 beat Fulcrum Therapeutics' score of 0.18 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sana Biotechnology is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.21	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Fulcrum Therapeutics has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

Fulcrum Therapeutics' return on equity of -25.38% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Sana Biotechnology	N/A	-103.02%	-39.16%

Summary

Fulcrum Therapeutics beats Sana Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Lexicon Pharmaceuticals?

Fulcrum Therapeutics (NASDAQ:FULC) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Fulcrum Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Fulcrum Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Fulcrum Therapeutics' return on equity of -25.38% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Lexicon Pharmaceuticals has higher revenue and earnings than Fulcrum Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.21	N/A
Lexicon Pharmaceuticals	$49.80M	20.68	-$50.34M	-$0.15	N/A

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 114.38%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 96.54%. Given Fulcrum Therapeutics' higher possible upside, research analysts plainly believe Fulcrum Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.28 beat Fulcrum Therapeutics' score of 0.18 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fulcrum Therapeutics beats Lexicon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Forte Biosciences. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 3 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.38 beat Fulcrum Therapeutics' score of 0.18 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Forte Biosciences is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.21	N/A

Forte Biosciences presently has a consensus target price of $71.67, indicating a potential downside of 6.84%. Fulcrum Therapeutics has a consensus target price of $8.20, indicating a potential upside of 114.38%. Given Fulcrum Therapeutics' higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market.

Fulcrum Therapeutics' return on equity of -25.38% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

Summary

Fulcrum Therapeutics beats Forte Biosciences on 9 of the 12 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FULC vs. The Competition

Export

Metric	Fulcrum Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$291.84M	$3.98B	$7.28B	$12.75B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-3.16	11.63	271.35	24.10
Price / Sales	N/A	1,302.16	606.04	78.14
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.59	17.24	11.19	6.40
Net Income	-$74.88M	-$22.72M	$3.46B	$348.28M
7 Day Performance	-0.39%	2.94%	2.06%	1.17%
1 Month Performance	2.82%	9.84%	7.42%	5.34%
1 Year Performance	-44.40%	54.50%	24.67%	16.25%

Fulcrum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FULC Fulcrum Therapeutics	3.1236 of 5 stars	$3.83 -0.1%	$8.20 +114.4%	-44.3%	$291.84M	N/A	N/A	100
SVRA Savara	2.0068 of 5 stars	$5.37 flat	$10.14 +88.9%	+76.9%	$1.10B	N/A	N/A	20
KURA Kura Oncology	3.1566 of 5 stars	$12.33 +9.3%	$25.62 +107.7%	+55.4%	$1.09B	$77.23M	N/A	130	Analyst Forecast Insider Trade High Trading Volume
SANA Sana Biotechnology	2.1964 of 5 stars	$3.63 -1.4%	$9.33 +157.1%	+9.2%	$1.09B	N/A	N/A	380
LXRX Lexicon Pharmaceuticals	1.4318 of 5 stars	$2.41 +3.0%	$4.55 +88.8%	+93.3%	$1.07B	$49.80M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FULC) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulcrum Therapeutics (FULC) Competitors

FULC vs. SVRA, KURA, SANA, LXRX, and FBRX

How does Fulcrum Therapeutics compare to Savara?

Summary

How does Fulcrum Therapeutics compare to Kura Oncology?

Summary

How does Fulcrum Therapeutics compare to Sana Biotechnology?

Summary

How does Fulcrum Therapeutics compare to Lexicon Pharmaceuticals?

Summary

How does Fulcrum Therapeutics compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulcrum Therapeutics (FULC) Competitors

FULC vs. SVRA, KURA, SANA, LXRX, and FBRX

How does Fulcrum Therapeutics compare to Savara?

Which has stronger valuation & earnings, SVRA or FULC?

Which has more risk & volatility, SVRA or FULC?

Do insiders and institutionals have more ownership in SVRA or FULC?

Does the media refer more to SVRA or FULC?

Is SVRA or FULC more profitable?

Do analysts prefer SVRA or FULC?

Summary

How does Fulcrum Therapeutics compare to Kura Oncology?

Do institutionals & insiders have more ownership in KURA or FULC?

Do analysts prefer KURA or FULC?

Which has more risk & volatility, KURA or FULC?

Does the media favor KURA or FULC?

Which has better earnings & valuation, KURA or FULC?

Is KURA or FULC more profitable?

Summary

How does Fulcrum Therapeutics compare to Sana Biotechnology?

Do analysts rate FULC or SANA?

Does the media prefer FULC or SANA?

Do institutionals & insiders hold more shares of FULC or SANA?

Which has higher earnings & valuation, FULC or SANA?

Which has more risk & volatility, FULC or SANA?

Is FULC or SANA more profitable?

Summary

How does Fulcrum Therapeutics compare to Lexicon Pharmaceuticals?

Which has more risk & volatility, FULC or LXRX?

Is FULC or LXRX more profitable?

Which has stronger earnings & valuation, FULC or LXRX?

Do analysts rate FULC or LXRX?

Do institutionals & insiders hold more shares of FULC or LXRX?

Does the media refer more to FULC or LXRX?

Summary

How does Fulcrum Therapeutics compare to Forte Biosciences?

Does the media favor FBRX or FULC?

Which has preferable valuation and earnings, FBRX or FULC?

Do analysts rate FBRX or FULC?

Do insiders and institutionals believe in FBRX or FULC?

Which has more risk and volatility, FBRX or FULC?

Is FBRX or FULC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools